Hepatic Artery Injection of 131I-Metuximab Combined with Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Prospective Nonrandomized, Multicenter Clinical Trial
| Autor: | Hai-Feng Xu, Renjie Yang, Hui Chen, Lin-Zhong Zhu, Ding Wei, Ziyu Li, Yu-Jun Shao, Hai-Chun Liu, Xu Zhu, Guang Cao, Xin Zhang, Jing Li, Zhi-Nan Chen, Gang Nan, Ling-Ming Kong, Jian-Feng Wang, Wuwei Yang, Chunyi Hao, Kun Gao, Ming Huang, Jian-Hai Guo, Peng Liu, Ren-You Zhai, Xiao-Yong Zhang, Huijie Bian, Ding Rong, Baorang Zhu, Ling Zhao, Song Gao, Xiaodong Wang, Kun Wang, Ling Wang, Baocai Xing, Jielai Xia |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Hazard ratio Hepatology medicine.disease Gastroenterology Confidence interval Clinical trial Hepatocellular carcinoma Internal medicine Radionuclide therapy medicine Radiology Nuclear Medicine and imaging Transcatheter arterial chemoembolization business Adjuvant |
| Zdroj: | Journal of Nuclear Medicine. 63:556-559 |
| ISSN: | 2159-662X 0161-5505 |
| Popis: | This prospective non-randomized, multicenter clinical trial was performed to investigate efficacy and safety of 131I-labeled metuximab in adjuvant treatment of unresectable hepatocellular carcinoma. Methods: Patients were assigned to treatment with transcatheter arterial chemoembolization (TACE) combined with 131I-metuximab or TACE alone. The primary outcome was overall tumor recurrence. The secondary outcomes were safety and overall survival. Results: The median time to tumor recurrence was 6 months in the TACE+131I-metuximab group (n = 160) and 3 months in the TACE group (n = 160) (hazard ratio, 0.55; 95% confidence interval, 0.43 to 0.70; P < 0.001). The median overall survival was 28 months in the TACE+131I-metuximab group and 19 months in the TACE group (hazard ratio, 0.62; 95% confidence interval, 0.47 to 0.82; P = 0.001). Conclusion: TACE+131I-metuximab showed a greater anti-recurrence benefit, significantly improved the 5-year survival of patients with advanced hepatocellular carcinoma, and was well tolerated by patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|